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Abstract
Objectives While many countries have robust child
immunization programs and high child vaccination cover-
age, vaccination of adults has received less attention. The
objective of this study was to describe the adult vaccination
policies in developed countries.
Methods From 2010 to 2011, we conducted a survey of
33 advanced economies as defined by the International
Monetary Fund. The survey asked about national recom-
mendations for adults for 16 vaccines or vaccine
components, funding mechanisms for recommended adult
vaccines, and the availability of adult vaccination coverage
estimates.
Results Thirty-one of 33 (93.9 %) advanced economies
responded to the survey. Twelve of 31 (38.7 %) reported
having a comprehensive adult immunization schedule. The
total number of vaccines or vaccine components recom-
mended for adults ranged from one to 15 with a median of 10.
Seasonal influenza (n = 30), tetanus (n = 28), pneumococ-
cal polysaccharide (n = 27), and hepatitis B (n = 27) were
the most frequently recommended vaccines or components.
Conclusions Approximately two-thirds of survey
respondents do not have a comprehensive adult vaccine
schedule, and most do not measure vaccination coverage.
We found that a funding mechanism is available for most
recommended adult vaccines.
Keywords Adult immunization  Vaccination policy 
Vaccination coverage  Vaccine financing 
Developed country  Advanced economy
Introduction
Vaccines are one of the most cost-effective strategies to
prevent infectious diseases among children, adolescents,
and adults. Globally, vaccination saves an estimated 2–3
million lives each year. (WHO and UNICEF 2005) Many
developed countries have robust child vaccination pro-
grams, and initiatives, such as the Expanded Programme on
Immunisation and the Global Alliance for Vaccines and
Immunisation, are helping developing countries build
childhood immunization infrastructures and introduce new
vaccines. (Levine et al. 2011) In contrast to the importance
placed on childhood vaccination, less attention has been
paid to adult immunization, even in developed countries
with strong public health infrastructures. (Advisory Coun-
cil for the Elimination of Tuberculosis and Advisory
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Committee on Immunization Practices 1996; Lang et al.
2011; Levine et al. 2011).
Vaccinating adults against infectious diseases is
important because adults can be carriers of infectious dis-
eases to the susceptible, and immunity from childhood
immunizations wanes with age, leading to disease out-
breaks such as pertussis in the United States. (Zepp et al.
2011) Additionally, many vaccines are most effective
among the healthy, and it is good clinical practice to vac-
cinate healthy adults before they develop chronic
conditions that are contraindications for vaccination or
make vaccines less effective. Some vaccine-preventable
diseases can become more severe with increasing age.
Some adults were not vaccinated as children. Last, with
increasing globalization, more and more people travel
across borders and are susceptible to infectious diseases
that are not endemic in their home country.
Successful childhood vaccination programs contain
policies recommending vaccination, effective funding
mechanisms, and routine vaccination coverage assessment.
To better understand adult vaccine policies, we conducted
a survey in 2010–2011 of 33 advanced economies around
the world as defined by the International Monetary Fund in
2009. (International Monetary Fund October 2009) We
asked about adult vaccination schedules, vaccine recom-
mendations, vaccine funding mechanisms, and vaccination
coverage availability and estimates. We also investigated
the associations of having adult vaccine policies in place
with the population size, per capita gross domestic product
(GDP), per capita expenditure on health, and out-of-pocket
spending on health.
Methods
To understand the prior literature on vaccine recommen-
dations and vaccine coverage for adults in developed
countries, we performed a PubMed/MEDLINE and Internet
search for adult vaccine schedules and/or recommendations.
The majority of the literature presented influenza vaccina-
tion coverage, with a few papers presenting vaccination
coverage for other vaccines such as pneumococcal, hepatitis
B, and tetanus vaccines. (Bader and Egler 2004, 2009;
Beytout et al. 2004; Blank et al. 2009; de Miguel 2006; del
Corro et al. 2009; Gavazzi et al. 2007; Kwong et al. 2007;
Leggat et al. 2009; Montrieux et al. 2002; Nielsen et al.
2009; Noakes et al. 2006; Pebody et al. 2008; Sammarco
et al. 2004; Schenkel et al. 2008; Stuck et al. 2007; van
Houdt et al. 2009) We were unable to identify published
literature that discussed a comprehensive adult vaccine
schedule and adult vaccine financing in developed coun-
tries. To determine the denominator, we used the
International Monetary Fund’s (2009) classification of
advanced economies (N = 33). (International Monetary
Fund October 2009) This definition includes two special
administrative regions (SARs) (Hong Kong SAR and Tai-
wan Province of China), and 31 countriesin North America,
Europe, and Asia (see Table 1 for list of advanced
economies).
Instrument
In March–April 2010, we developed a survey instrument
that included questions about the availability of an adult
vaccine schedule, recommendations for adults to receive
specific vaccines or be vaccinated against certain diseases
Table 1 Advanced economies surveyed, abbreviations, and valida-








Belgium x BE x
Canada x CA
Cyprus x CY x
Czech Republic x CZ x
Denmark x DK x
Finland x FI
France x FR x
Germany x GE
Greece x GR x
Hong Kong, SAR China x HK
Iceland x IC
Ireland x IR x
Israel
Italy x IT x
Japan x JP
Luxembourg x LU
Malta x MT x
Netherlands x NL
New Zealand x NZ
Norway x NO x
Portugal x PT x
Republic of Korea x KO
Singapore
Slovak Republic x SK x
Slovenia x SL
Spain x SP x
Sweden x SD x
Switzerland x SW
Taiwan, Province of China x TW
United Kingdom x UK x
United States x US
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[for 16 vaccines or vaccine components: diphtheria,
Bacillus Calmette-Guérin (BCG), hepatitis B, hepatitis A,
herpes zoster, human papillomavirus (HPV), measles,
meningococcal, mumps, pertussis, poliomyelitis (polio),
pneumococcal, rubella, seasonal influenza, tetanus, and
varicella], vaccine financing for recommended adult vac-
cines (public or private as applicable), availability of
vaccination coverage estimates among adults, and vacci-
nation coverage for recommended adult vaccines. We
asked about vaccine components because countries have
different vaccine formulations and combinations, depend-
ing on disease epidemiology and products offered by
vaccine manufacturers. For questions on availability of
private funding, we asked if a legal requirement in the
country or SAR for private insurance to pay for vaccination
for one or more groups of adults was in place, and, if so, to
indicate for which groups of adults (e.g., specific age
groups, those with medical conditions, travelers, at-risk
employees, the disabled). We also asked if countries rec-
ommended other vaccines against vaccine-preventable
diseases for adults in addition to the 16 we specifically
asked about.
The questionnaire was administered using two formats:
a web-based survey and a Microsoft (MS) Word survey
sent via email. The web-based survey was pilot tested in
four advanced economy countries (France, Ireland, Italy,
and United States) in May–June of 2010. After appropriate
changes were made based on the pilot test results, the web-
and MS Word-based surveys were sent to vaccination
policy contacts in each country and SAR in late June 2010.
Data collection
For the advanced economies in the European Union plus
Norway and Iceland (22 countries), we collaborated with
the Vaccine European New Integrated Collaboration Effort
II (VENICE II) to implement the web-based survey in
SurveyMonkey (SurveyMonkey.com, LLC). Representa-
tives from the national ministry of health or related
national organization responsible for vaccine policies were
invited to complete the survey. For a full list of VENICE II
country gatekeepers, please see http://venice.cineca.org/
participating_countries.html. For the non-VENICE II
advanced economies, we worked with representatives from
the Australia Department of Health and Aging; the Public
Health Agency of Canada; The Department of Health Hong
Kong; the National Institute of Infectious Disease, Japan;
The Korea Centers for Disease Control and Prevention; the
University of Otago in New Zealand; and the Taiwan
Centers for Disease Control and Prevention. If invited
participants did not respond, web searches of publicly
available vaccine schedules and policies published by the
national ministry of health were performed to fill data gaps.
VENICE II served as the data collectors and managers
for the web-based survey, and responded to questions
regarding the survey. Countries that completed the web-
based survey were asked to validate their data by reviewing
their responses and updating them as necessary. Data col-
lection continued through February 2011. For the
remaining 11 countries and SARs, we administered the MS
Word-based survey via email that contained the same
questions as the web-based survey. Data on seasonal
influenza, hepatitis B, and HPV vaccines were available
from published reports of recent VENICE II surveys in
2008, 2009, and 2010, respectively. (Dorleans et al. 2010;
Mereckiene et al. 2008, 2010) For survey respondents that
did not provide an estimate for vaccination coverage for
hepatitis B, data from published reports were used to
supplement the data. (Bader and Egler 2004; Nielsen et al.
2009; Schenkel et al. 2008; Schiller and Euler 2008; van
Houdt et al. 2009).
Analysis
Data from the web- and MS Word-based surveys were
aggregated and analyzed using MS Excel 2007. We cal-
culated the total, mean, and median number of vaccines
recommended for adults in each advanced economy. For
each of the 16 vaccines or components, we examined the
groups of adults for which vaccines were recommended,
the availability and type of funding, the availability of
vaccination coverage estimates, and vaccination coverage
for recommended adult vaccines.
We also examined the relationships between adult vac-
cine policies and characteristics of the advanced economy
using bivariate logistic regression analyses. Odds ratios
(ORs) were calculated in SAS (SAS Institute Inc. 2008)
using the Proc Logistic procedure. The outcomes examined
were availability of a comprehensive adult vaccine sche-
dule (yes/no), recommendations for any group of adult to
receive vaccination for a particular vaccine or component
(yes/no), availability of any funding (public or private) for
a recommended adult vaccine or component (yes/no), and
availability of a vaccination coverage estimate for a rec-
ommended adult vaccine or component (yes/no). Data for
the predictor variables were gathered from the World Bank.
(The World Bank 2010a, b, c, d) Predictor variables
examined were population (as of 2009), GDP per capita
(current $US as of 2009), health expenditure per capita
(current $US as of 2009), and out-of-pocket health
expenditure (% of private expenditure on health as of
2009). For the outcome ‘‘Comprehensive Adult Immuni-
zation Schedule (yes/no),’’ one OR was calculated for each
of the four continuous predictor variables. For the out-
comes ‘‘Recommendation (yes/no),’’ ‘‘Any Funding (yes/
no),’’ and ‘‘Coverage Estimate Available (yes/no),’’ meta-
International variation in adult vaccination recommendations 867
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analysis was used to produce pooled ORs. First, for each of
the four predictor variables, ORs were calculated when
data were sufficient for each of 16 vaccines. The separate
vaccine ORs were pooled into one OR for each predictor/
outcome combination using the R meta-analysis package
named metafor. (Viechtbauer 2010).
The coauthors of this study, except for J. Crumly, also
published the results of this survey for VENICE II
member countries only in a separate paper. (Kanitz et al.
2012) The VENICE II consortium includes European
countries not classified as advanced economies that are
not included in the present analysis. The VENICE II only
analysis also examines the types of vaccine components
recommended, funding, and availability of coverage
estimates for adult vaccines, but does not analyze the
relationships between adult vaccine policies and charac-
teristics of the countries. The current manuscript
highlights findings from a group of countries and SARs
with comparable economies, whereas the VENICE II only
paper reports results for a group of countries sharing a
common geographic location.
Results
Thirty-one of 33 (93.9 %) advanced economies responded
to the survey; Israel and Singapore did not provide
responses. The data were validated in 15 of 31 (48.4 %)
advanced economies (Table 1). The age of adulthood for
immunization purposes ranged from 15 (Spain) to 19
(Slovenia) years, with a median of 18 years. Twelve of 31
(38.7 %) advanced economies had a comprehensive adult
vaccine schedule which describes the country or SAR’s
adult vaccine recommendations in one document. The total
number of vaccines or vaccine components recommended
for adults ranged from one to 15 with a median of 10.
Having a comprehensive adult vaccine schedule was
associated with recommending more vaccines for adults
[odds ratio (OR) = 1.38, 95 % confidence interval (CI):
1.007–1.891, p value 0.0452].
Descriptives
Figure 1 shows the number of advanced economies that
recommend vaccination for 16 vaccines or components for
one or more groups of adults. This figure also indicates
whether the recommendations are for all adults or for
specific risk groups and travelers to disease-endemic areas.
Specific risk groups include recommendations for particu-
lar age groups (e.g., older adults), adults with health
conditions, at-risk employees including health care work-
ers, and the disabled. For example, 30 (96.8 %) advanced
economies recommend adults be vaccinated seasonally
against influenza. Of these, two (6.7 %) recommend for all
adults and 28 (93.3 %) recommend influenza vaccination
for specific groups of adults.
The most frequently recommended vaccines for adults
are seasonal influenza (n = 30), hepatitis B (n = 27),
pneumococcal (n = 27), tetanus (n = 26), and diphtheria
(n = 26). The least frequently recommended vaccines for
adults are Bacille Calmette-Guerin (BCG) (n = 10),
mumps (n = 10), HPV (n = 5), and herpes zoster (n = 5).
Most adult vaccines are recommended for specific risk
groups and travelers, with the exceptions of tetanus,
diphtheria, and pertussis.
Figure 2 shows the type of funding mechanism (public
funding only, private funding only, public and private
funding, or no funding) for recommended adult vaccines in
advanced economies for the same 16 vaccines or compo-
nents shown in Fig. 1. These funding mechanisms are for
one or more groups of adults. Private funding indicates that
a legal requirement for private health insurance to pay for
vaccination for that particular vaccine or component is in
place. As an example, seasonal influenza vaccine is
financed through public funds only in 26 of 30 respondents
(86.7 %) and through public and private funding in three
(10.0 %) advanced economies. Although seasonal influ-
enza vaccine is recommended for adults, no funding is
provided for the vaccine in one (3.3 %) advanced econ-
omy. Most recommended adult vaccines are financed
through public funds only. Pneumococcal (26.3 %), polio
(50.0 %), varicella (41.7 %), pertussis (40.0 %), mumps
(25.0 %), and HPV (33.3 %) vaccines have no funding
mechanism for adults in 25 % or greater of recommending
advanced economies.
At least one advanced economy had a coverage estimate
available for each of the 16 recommended adult vaccines or
components for one or more groups of adults. Seasonal
influenza vaccination coverage was the most commonly
measured, with 29 (96.7 %) of advanced countries indi-
cating a vaccination coverage estimate for adults is
available. After seasonal influenza, the vaccines for which
coverage was most commonly measured were hepatitis B
[n = 11 (42.3 %)] and tetanus [n = 8 (30.8 %)]. Six rec-
ommending advanced economies each had vaccination
coverage estimates for diphtheria (28.6 %) and pneumo-
coccal (35.3 %). Four recommending advanced economies
had vaccination coverage estimates for hepatitis A
(22.2 %). Three recommending advanced economies had a
vaccination coverage estimate for the polio vaccine
(15.8 %). One advanced economy had a vaccination cov-
erage estimate available each for varicella (5.9 %), measles
(6.3 %), mumps (6.7 %), rubella (6.3 %), meningococcal
(6.7 %), pertussis (5.6 %), BCG (7.1 %), HPV (16.7 %),
and herpes zoster (25.0 %). (Please note: the Australian
Institute of Health and Welfare released the results of the
868 L. A. Wu et al.
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2009 Adult Vaccination Survey on March 3, 2011. To
maintain comparability across the study period March
2010–February 2011, we do not include the results here.)
Figure 3 shows seasonal influenza vaccination coverage
for adults C65 years for the most recent influenza season
for which data are available between 2006 and 2010 for 23
advanced economy countries (the data for Taiwan are for
all adults C18 years.). The Figure also shows the type of
funding mechanism for seasonal influenza vaccine. Vac-
cination coverage ranged from 82 % in the Netherlands to
25 % in the Czech Republic. Coverage in Taiwan was
12 %. Despite not having any funding for seasonal influ-
enza vaccine for adults, the coverage estimate for adults
C65 years in Norway (50 %) was higher than in seven
advanced economies that do have a funding mechanism for
the vaccine. The seasonal influenza vaccination coverage
among adults C65 years in these seven advanced econo-
mies was 31 % in the Slovak Republic, 25 % in the Czech
Republic, 48 % in Finland, 38 % in Spain, 35 % in Ger-
many, 33 % in Austria, and 29 % in Slovenia.
Table 2 shows vaccination coverage estimates among
adults for tetanus and hepatitis B vaccines for recom-
mending advanced economies where data were available.
In six advanced economies, tetanus vaccination coverage
ranged from 47 % among all adults (C18 years) in Canada
to 71 % among all adults (C18 years) in France. The tet-
anus coverage estimate was 6 % among 16- 24-year-olds in
New Zealand and 95 % among 25- 44-year-olds also in
New Zealand. However, the estimates in New Zealand
were based on a national serosurvey conducted among 597
individuals rather than vaccination coverage measurement.
(Weir et al. 2009).
Fig. 1 Advanced economies
that recommend vaccines for
adults, 2010, survey of adult
vaccination policies in advanced
economy countries (n = 30).
Specific risk groups = age,
health condition, at-risk
employee (including health care
worker), disabled. Travelers are
individuals that travel to
disease-endemic areas
Fig. 2 Type of funding
mechanisms for recommended
adult vaccines, 2010, survey of
adult vaccination policies in
advanced economy countries
(n = 30). Private
funding = legal requirement for
private health insurance to pay
for vaccination
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Hepatitis B vaccination coverage is shown by age
groups and by risk groups of adults in Table 2. Among
younger adults (from the adult age threshold up to
49 years), hepatitis B vaccination coverage ranged from
8 % in Denmark to 58 % in Canada. Among older adults
(C50 years), there is one estimate for Germany at 33 %
coverage. Among health care workers, hepatitis B vacci-
nation coverage ranged from 22 % in Germany to 100 % in
the Czech Republic. For adults in behavioral risk groups,
coverage ranged from 45 % among intravenous drug users
(IDU) in Finland to 62 % in a sample of men who have sex
with men, commercial sex workers, and IDU in the
Netherlands.
Regression analyses
In Table 3, we show results of bivariate logistic regression
analyses for the associations between advanced economy
characteristics (population, GDP per capita, health expen-
diture per capita, and out-of-pocket health expenditure) and
adult immunization strategies (adult immunization sche-
dule, recommendation for a particular vaccine or
component, any funding for a particular vaccine or com-
ponent, and coverage estimate available for a particular
vaccine or component). We adjusted the scale for popula-
tion (to population per 5 million), GDP per capita (to GDP
per capita per US $5,000), and health expenditure per
capita (to health expenditure per capita for US $1,000) so
the results would have a practical interpretation. Population
per five million was associated with slightly increased odds
of having a coverage estimate available. There was a
marginally statistically significant reduced odds of having
any funding available for the 16 vaccines or components as
GDP per capita per US $5,000 increases (pooled
OR = 0.94, 95 % CI 0.86–1.03). Both GDP per capita and
health expenditure per capita were related to an increased
probability of recommendation for vaccines, while
increasing out-of-pocket health expenditure was associated
with decreased odds of a recommendation for a vaccine
and having a coverage estimate available (see Table 3).
Recommendation for vaccination was related to having a
comprehensive adult immunization schedule (pooled
OR = 1.73, CI 1.30–2.29). Please note this finding is not
reported in Table 3.
Discussion
This survey is the first to describe the range of adult vac-
cine strategies, policies, and funding sources in 31
advanced economies. Roughly one-third of the advanced
economies have a comprehensive adult immunization
schedule that summarizes their recommendations. We
found a correlation between having a comprehensive adult
immunization schedule and recommending more vaccines
for adults. Although the confidence interval was wide, this
finding could indicate that the importance of adult vacci-
nation and the perception of the severity of vaccine-
preventable diseases may vary from place to place.
We found the most frequently recommended vaccines
for adults are seasonal influenza, tetanus, diphtheria,
pneumococcal, and hepatitis B. These data are not sur-
prising given that these five vaccines have been widely
used for more than 30 years and were more often initially
recommended for adults rather than children compared
with other vaccines, such as varicella or polio. (Hinman
and Orenstein 2007; Michel and Lang 2011; Poland et al.
2010; Roush and Murphy 2007) The least frequently rec-
ommended adult vaccines are BCG, HPV, mumps, and
herpes zoster. BCG vaccination has varying efficacy
against tuberculosis, especially among adults (ACIP 1990),























Country or Special Administrative Region with Advanced 
Economy
Fig. 3 Seasonal influenza
vaccination coverage estimates
by advanced economy and type
of funding for adults C65 years,
most recent from 2006 to 2010
(n = 23) a Legal requirement
for private health insurance to
pay for vaccination b Data for
New Zealand from a national
serosurvey by the New Zealand
Ministry of Health from Oct
2005 to Feb 2007, n = 597 c
Data for Taiwan for all adults
C18 years. Source: Centers for
Disease Control and Prevention
(2010), Kwong et al. (2007),
Mereckiene et al. (2008),
Hajime Kamiya (Personal
communication)
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also found most adult vaccines are recommended for spe-
cific groups of adults rather than recommended to all
adults, consistent with cost effectiveness and indications
for most of these vaccines. The age threshold of adults
defined by the surveyed countries ranged from 15 to
19 years, which may affect the comparability of the survey
results.
Lowering the financial barriers to receiving vaccines
increases vaccine uptake. (The Community Guide 2008)
Therefore, an effective funding mechanism for adult vac-
cines is an important part of a comprehensive
immunization strategy. Our results indicate increasing
GDP per capita and increasing health expenditure per
capita are associated with increased likelihood of a rec-
ommendation for a vaccine. We also found the majority of
recommended adult vaccines are funded through public
funds only. No international system of classifying health
systems currently exists, and advanced economies may
Table 2 Tetanus and hepatitis B vaccination coverage estimates for adults in recommending advanced economies, 2010, survey of adult
vaccination policies in advanced economy countries
Advanced economy Type of funding Vaccination coverage (%) Years
Tetanus
Canada Public only All adults 47 2006
France Public only All adults 71 2002
Germany Public only All adults 73 2009
Malta Public only 16 yearsa 55 2009
New Zealandb Public only 16–24 years 6 2007
25–44 years 95
C45 years 89
Portugal Public only 65 years 61 2010
United States Public only 19–49 years 64 2008
50–64 years 62
C65 years 52
Hepatitis B, by age groups
Canada Public only 18–49 years 58 2006
Denmark (Nielsen et al. 2009) Public only 18–49 years 8 2007
Germany (Bader and Egler 2004) Public and privatec 18–49 years 46 2003
50–59 years 33
C60 years 33
United States (Schiller and Euler 2008) Public only 19–49 years, not hr 34 2008
19–49 years, hr 32
Hepatitis B, by risk groups
Czech Republic Public and private HCW 100 2007
Finland Public only IDU 45 2004
France Public only HCW 87 1999
Germany (Schenkel et al. 2008) Public only Chronic condition 70 2004
HCW 22
Netherlands (van Houdt et al. 2009) Public only MSM, CSW, IDUd 62 2002–2007
Slovakia Public and private HCW 88 2007
Hemodialysis patients 96
United States Public only HCW 69 2008
Norway has tetanus vaccination coverage for adults available but did not provide the estimate
hr High risk, HCW health care workers, IDU intravenous drug users, MSM men who have sex with men, CSW commercial sex workers
a Malta recommends a 5th dose of tetanus vaccine at 16 years but the age of adulthood is 18 years
b From a national serosurvey by the Ministry of Health from Oct 2005–Feb 2007, n = 597
c Public and private funding indicates public funding is available and there is a legal requirement for private health insurance to pay for
vaccination
d From a sample of MSM, CSW, and IDU
Source Nielsen et al. (2009); Bader and Egler (2004); Schiller and Euler (2008); Schenkel et al. (2008); van Houdt et al. (2009)
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define public and private funding differently. The type of
funding available may also be limited to public only if the
advanced economy has a centrally run national health care
system, such as the National Health Service in the UK.
Most recommended adult vaccines have a source of
funding, whether it is public or private, but it is important
to note that pneumococcal, polio, pertussis, varicella,
mumps, and HPV vaccines do not have a funding mecha-
nism in more than 25 % of recommending advanced
economies. This lack of funding may be related to the
length of time the vaccine has been recommended for
adults, the epidemiology of disease burden, competing
health interests, or the process of making vaccine recom-
mendations in each advanced economy. In the survey, we
asked for the year when a vaccine recommendation for
adults was first made for each vaccine or component, but
the majority of respondents did not provide a response. We
did not have enough data to examine the relationship
between funding mechanisms and health expenditure per
capita. It may be that, as more government funds are spent
on health in general, the need to fund adult vaccination is
less perceived. However, this finding could be confounded
by health care efficiency, as increased spending on health
per capita does not necessarily correlate with improved
quality of care. (Anderson and Frogner 2008) We did not
ask about the processes of making vaccine recommenda-
tions in each advanced economy, which could be valuable
in understanding the factors influencing adult vaccine
policies. These could include deliberations by national or
regional vaccine advisory committees, and how often
vaccine policies are reviewed and updated. This informa-
tion could be useful to understanding the decision-making
process around vaccines and the relative importance of
adult vaccination compared with other health priorities.
Vaccination coverage measurement is vital to evaluating
immunization program progress. We found that, for all 16
vaccines or components except for seasonal influenza, the
majority of recommending advanced economies do not
have a coverage estimate available. The financial and
structural resources needed for regular vaccination cover-
age measurement can be substantial, and adult vaccination
may not be a health priority in many of these advanced
economies.
We described vaccination coverage estimates for the
three vaccines for which we have the most data: seasonal
influenza, tetanus, and hepatitis B. Coverage rates vary
substantially across similar age or risk groups. For seasonal
influenza vaccine among adults 65 years and older, many
advanced economies have reached coverage rates above
60 %, with a high of 82 % in the Netherlands. In com-
parison, a number of advanced economies have coverage
below 40 % among the same age group. This may be
related to the degree to which regular seasonal influenza
vaccination is a long-standing part of preventive care.
We received responses from over 90 % of the invited
respondents, and while the data are based on self-report,
these were validated in roughly half of the respondents.
Some respondents expressed confusion about the meaning
of a vaccine ‘‘recommendation,’’ and we received some
comments that a vaccine recommendation could be made
by a range of groups, including the government or Ministry
of Health and also by health care provider associations and
vaccine manufacturers. Because this was a survey of adult
vaccine policies, we asked about vaccines recommended
by the government, Ministry of Health, or another official
policy-making body in the advanced economy. We did not
ask about the vaccine safety systems in these advanced
economies, which is another important component of a
vaccination program.
While ongoing vaccine uptake measurement can be
resource intensive, guidelines to establishing such systems
may be helpful for these advanced economies. A consensus
Table 3 Results of logistic regression analysis, 2010, survey of adult vaccination policies in advanced economy countries










Per 5 million population 1.08 (0.96–1.22) 1.01 (0.98–1.03) 1.00 (0.95–1.06) 1.05 (1.00–1.09)
GDP per capita per $US5000 0.92 (0.71–1.18) 1.10 (1.02–1.19) 0.94 (0.86–1.03) 0.96 (0.86–1.06)
Health expenditure per capita per $US1000 1.00 (0.64–1.57) 1.33 (1.16–1.53) – 1.06 (0.88–1.27)
Out of pocket health expenditure in percentc 0.93 (0.87–1.00) 0.96 (0.95–0.98) 1.01 (0.99–1.03) 0.97 (0.95–0.99)
a Diphtheria, Bacillus Calmette-Guérin (BCG), hepatitis B, hepatitis A, herpes zoster, human papillomavirus (HPV), measles, meningococcal,
mumps, pertussis, poliomyelitis (polio), pneumococcal, rubella, seasonal influenza, tetanus, and varicella
b Data from the World Bank (see ‘‘Methods’’)
c Percent of total private expenditure on health
d Bold: p value for test statistic \0.05
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statement issued by the European Union Geriatric Medi-
cine Society and International Association of Gerontology
and Geriatrics-European Union in 2009 advocated for
strengthening and harmonizing vaccine strategies for adults
60 years and older at the European level. (Michel et al.
2009) Policies and programs are important not only for
older adults, but for all adults to protect the well-being and
health of the entire population. Advanced economies are
experiencing aging of their populations, and with contin-
uing improvements in medicine and the quality of life,
public health will need to consider a shift in funding from
childhood-based vaccination programs to ‘‘lifespan’’ pro-
grams. (Michel and Lang 2011; Poland et al. 2010).
The reduced effectiveness of some adult vaccines when
compared with childhood vaccines may be a barrier to
increased uptake. (Osterholm et al. 2012) As the number of
available vaccines continues to increase, standards for
vaccination strategies will ease the introduction of new
vaccines into existing vaccination practices. An increasing
role exists for non-traditional/non-medical home immuni-
zation providers, such as pharmacists and community
vaccinators, and standards should include considerations
for partnering with these health providers. (Postema and
Breiman 2000).
Conclusions
We have demonstrated policies recommending vaccination
for adults, funding mechanisms for adult vaccine admin-
istration, and routine adult vaccination coverage
assessment vary and are often lacking in the countries with
advanced economies surveyed. Newer vaccines are less
likely to be recommended for adults than older ones.
Funding of adult vaccination is associated with recom-
mendations for adult vaccine use. Most recommended adult
vaccines are funded with public funds alone. These ele-
ments of stable funding, standard recommendations, and
routine vaccine coverage assessment are essential compo-
nents of successful childhood immunization programs. For
adult vaccination to be as effective as childhood programs,
countries should strive to include them for their adult
populations.
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